Pacific Edge

Pacific Edge Enterprise Value

The Enterprise Value (EV) of Pacific Edge (PEB.NZ) as of Nov 15, 2026 is 164.40 M NZD. In the previous year, Enterprise Value (EV) was 137.88 M NZD — a change of 19.24% (higher).

Enterprise Value

164.40 MNZD

YoY

19.24%

Last updated:

Enterprise Value (EV) of Pacific Edge is 2025 164.40 M NZD. Enterprise Value (EV) of Pacific Edge was 2024 137.88 M NZD. It decreases by 19.24% higher compared to the previous year.

The Pacific Edge Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
167.92 M NZD
Jan 1, 2019
171.30 M NZD
Jan 1, 2020
170.84 M NZD
Jan 1, 2021
163.82 M NZD
Jan 1, 2022
80.58 M NZD
Jan 1, 2023
107.50 M NZD
Jan 1, 2024
137.88 M NZD
Jan 1, 2025
164.40 M NZD
The Pacific Edge Enterprise Value history
YEAREnterprise ValueYoY
164.40 MNZD+19.24%
137.88 MNZD+28.26%
107.50 MNZD+33.41%
80.58 MNZD-50.81%
163.82 MNZD-4.11%
170.84 MNZD-0.27%
171.30 MNZD+2.01%
167.92 MNZD-0.93%
169.50 MNZD+6.00%
159.91 MNZD-9.27%
176.25 MNZD+7.71%
163.63 MNZD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pacific Edge Stock analysis

What does Pacific Edge do? Pacific Edge Ltd is a company based in New Zealand specializing in the development and marketing of cancer diagnostic test systems. The company was founded in 2001 and has since become a leading provider of cancer detection systems in New Zealand and other countries. Pacific Edge's business model is based on the development and marketing of non-invasive diagnostic methods for early cancer detection. The tests offered are based on the analysis of urine samples, which are analyzed using state-of-the-art technologies to detect specific proteins in the urine that are typically associated with cancer. These tests enable doctors and patients to detect cancer at an early stage, increasing treatment and cure rates. Pacific Edge specializes in three main areas: urology, gynecology, and bladder cancer. The urology division focuses on the development of diagnostic tests for prostate cancer. It is one of the most common types of cancer in men, and early detection is known to increase the chance of a complete cure. Tests such as Cxbladder enable doctors to detect prostate cancer at an early stage. Pacific Edge's gynecology division focuses on the development of diagnostic tests for the early detection of cervical cancer. Currently, the Pap test is used in many countries to detect the presence of cancer cells in the cervix. However, the Cxbladder diagnostic test can detect the presence of certain proteins in the urine that indicate a cancerous condition, without the need for invasive procedures. The third pillar of Pacific Edge is the bladder cancer division. The Cxbladder test enables doctors to detect bladder cancer at an early stage. Currently, there are few effective screening methods for bladder cancer. However, the Cxbladder test can help detect bladder cancer at an early stage, improving treatment and cure rates. In addition to the three main areas, Pacific Edge also develops new diagnostic products for other types of cancer. These include cancers such as colon cancer, lung cancer, and kidney cancer, as well as rare cancers such as pancreatic cancer and esophageal cancer. Pacific Edge's products have already proven themselves in the medical community. They provide doctors and patients with an effective and cost-efficient way to detect cancer early. The company also conducts research and development to improve the accuracy and effectiveness of the tests offered. Pacific Edge is committed to expanding its business globally. It has already formed partnerships with some leading pharmaceutical and biotech companies to distribute its products on a global scale. The company has also established offices in Australia, the United States, and Singapore. In summary, Pacific Edge Ltd is a company specializing in the development and marketing of diagnostic tests for cancer. It focuses on the early detection of cancers such as prostate cancer, cervical cancer, and bladder cancer through the analysis of urine samples using state-of-the-art technologies. The company has established itself as a leading provider of cancer detection systems and conducts research and development to improve the accuracy and effectiveness of its products. Pacific Edge is committed to expanding its business globally and has already formed partnerships with leading companies in the pharmaceutical and biotech industry. Pacific Edge is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pacific Edge stock

Enterprise Value (EV) of Pacific Edge is 164.40 M NZD in 2025.

Enterprise Value (EV) of Pacific Edge changed from 137.88 M NZD to 164.40 M NZD, representing a 19.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Pacific Edge since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s NZD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' NZD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Pacific Edge with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Pacific Edge

All Key Metrics — Pacific Edge